BlackRock
LABP

BlackRock’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

BlackRock’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42
Closed -$154 – 5491
2023
Q4 		$154 Hold
42
– – ﹤0.01% 5325
2023
Q3 		$163 Hold
42
– – ﹤0.01% 5389
2023
Q2 		$177 Sell
42
-3,340
-99% -$10.6K ﹤0.01% 5452
2023
Q1 		$10.1K Buy
3,382
+944
+39% +$3.48K ﹤0.01% 5325
2022
Q4 		$12.2K Sell
2,438
-27,251
-92% -$104K ﹤0.01% 5439
2022
Q3 		$193K Sell
29,689
-1,785
-6% -$15.5K ﹤0.01% 4989
2022
Q2 		$229K Sell
31,474
-20,557
-40% -$187K ﹤0.01% 5002
2022
Q1 		$767K Buy
52,031
+4,988
+11% +$127K ﹤0.01% 4755
2021
Q4 		$2.26M Buy
47,043
+23,681
+101% +$2.49M ﹤0.01% 4356
2021
Q3 		$3.41M Sell
23,362
-6,042
-21% -$784K ﹤0.01% 4094
2021
Q2 		$3.4M Buy
29,404
+3,775
+15% +$421K ﹤0.01% 4049
2021
Q1 		$2.47M Buy
+25,629
New +$3.34M ﹤0.01% 4225

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
BMCM
Black Maple Capital Management Milwaukee, Wisconsin $179M AUM 8.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock's LABP Position: Q1 2024 in Review

BlackRock sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q1 2024, closing a stake of 42 shares — an estimated $154 sold.

BlackRock first reported a position in LABP in Q1 2021 and held it in 12 quarters. The position peaked at $3.41M in Q3 2021. 16 funds tracked by Wall St. Rank hold LABP as of Q1 2024.

  • BlackRock reported no remaining Landos Biopharma, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 42 Landos Biopharma, Inc. Common Stock shares in Q1 2024, an estimated $154.
  • BlackRock first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
  • BlackRock's Landos Biopharma, Inc. Common Stock position peaked at $3.41M in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.